-
公开(公告)号:WO2023070085A2
公开(公告)日:2023-04-27
申请号:PCT/US2022/078508
申请日:2022-10-21
Applicant: THE ROCKEFELLER UNIVERSITY
Inventor: BRADY, Sean , LI, Lei , KOIRALA, Bimal
Abstract: The present invention provides methods, compositions, and articles of manufacture useful for treatment of multi drug-resistant pathogens and related conditions. The present invention provides compositions and methods incorporating and utilizing menaquinone-binding compounds or derivatives or variants thereof.
-
公开(公告)号:WO2023044487A1
公开(公告)日:2023-03-23
申请号:PCT/US2022/076667
申请日:2022-09-19
Applicant: PEPTILOGICS, INC.
Inventor: STECKBECK, Jonathan D. , PICONE, Bradd N. , SAUER, John Michael , HUANG, David
Abstract: Provided in this disclosure are formulations and methods comprising antimicrobial peptides that can treat lung disease or injury when administered to a subject.
-
公开(公告)号:WO2023029001A1
公开(公告)日:2023-03-09
申请号:PCT/CN2021/116530
申请日:2021-09-03
Applicant: 深圳千越生物科技有限公司
Abstract: 本申请提供了一种抗菌肽或肽衍生物、替换体以及其组合物、制备方法和应用,其包括如下氨基酸序列I和II中的至少一种:氨基酸序列I:Xa1Ba1U1Z1Ba2Xa2Ba3Za2Ba4Xa3;氨基酸序列II如图;其中Xa1、Ba1、U1、Za1、Ba2、Xa2、Ba3、Za2、Ba4、Xa3、Xb1、Bb1、Ca1、Zb1、Bb2、Xb2、Bb3、Zb2、Bb4、Xb3、Ca2各自独立地选自天然氨基酸或/和非天然氨基酸。其中,本申请提供的抗菌肽或肽衍生物可以与细胞壁/膜的脂质结构结合,损坏其理化学性质,破坏微生物壁,进而杀死微生物和肿瘤细胞,另外,也具有外伤消毒、抗感染的功效。
-
公开(公告)号:WO2023284985A1
公开(公告)日:2023-01-19
申请号:PCT/EP2021/070036
申请日:2021-07-16
Applicant: DBV TECHNOLOGIES
Inventor: DIOSZEGHY, Vincent
Abstract: The invention relates to a method for increasing tolerance to cashew in a subject, comprising repeatedly administered a cashew allergen in combination with at least one regulatory Treg peptide from human immunoglobulin G (IgG) by epicutaneous route.
-
5.
公开(公告)号:WO2022255848A1
公开(公告)日:2022-12-08
申请号:PCT/KR2022/007954
申请日:2022-06-03
Applicant: 독립바이오제약(주)
Abstract: 본 발명은 Agkistrodon piscivorus piscivorus 및 Naja melanoleuca로부터 유래된 펩타이드 또는 이의 혼합물을 포함하는 조성물 및 이의 약학적 용도에 관한 것이다. 구체적으로 뱀의 일종인 Agkistrodon piscivorus piscivorus 및 Naja melanoleuca 뱀독으로부터 유래된 펩타이드 또는 이의 혼합물을 포함하는 베체트병 또는 류마티스 관절염의 예방 또는 치료용 조성물에 관한 것이다.
-
公开(公告)号:WO2022251484A1
公开(公告)日:2022-12-01
申请号:PCT/US2022/031115
申请日:2022-05-26
Applicant: APELLIS PHARMACEUTICALS, INC.
Inventor: SCHEIBLER, Lukas
IPC: A61K31/713 , A61P27/02 , A61K38/04 , A61K38/10 , C12Q1/6883 , C12N15/113
Abstract: Inappropriate or excessive complement activation is an underlying cause or contributing factor to a number of serious diseases and conditions, and considerable effort has been devoted over the past several decades to exploring various complement inhibitors as therapeutic agents. RNAs, such as miRNA and siRNA, and their use in treating complement-mediated disorders, are described.
-
公开(公告)号:WO2022247740A1
公开(公告)日:2022-12-01
申请号:PCT/CN2022/094056
申请日:2022-05-20
Applicant: 上海市第一人民医院
IPC: C07K7/08 , C12N15/12 , A61K38/10 , A61P37/02 , A61P17/06 , A61P19/02 , A61P25/00 , A61K38/00 , A61P1/00 , A61P11/06 , A61P17/00 , A61P29/00
Abstract: 本发明提供了一种多肽及其在制备免疫调节药物中的应用。所述的功能性多肽为长链非编码RNA LINC01871的host gene编码的新型多肽PEP20,其可在炎症环境中特异性靶向CD8 +T细胞,抑制CD8 +T细胞向Tc17细胞的分化,抑制Tc17细胞过度分化、过度增殖以及IL-17A的过度表达,具有免疫调节功能,可用于预防或治疗自身免疫性疾病,如银屑病、类风湿性关节炎与多发性硬化症等。本发明的PEP20分子量小,容易进入细胞发挥作用;且可通过化学方法合成,易于大量制备,稳定性好,相对于现有的治疗银屑病等自身免疫炎症性疾病的抗体价格更低、更安全。
-
8.
公开(公告)号:WO2022245553A2
公开(公告)日:2022-11-24
申请号:PCT/US2022/027836
申请日:2022-05-05
Applicant: SIGNABLK, INC.
Inventor: SIGALOV, Alexander
IPC: A61K38/08 , A61K38/10 , A61K38/17 , A61P11/00 , A61K39/395 , A61K39/44 , C07K7/06 , C07K7/08 , C07K14/47 , C07K17/00 , C07K9/00
Abstract: The present invention is related to the field of pulmonary therapeutics. In particular, the compositions described herein are used in methods of treating lung disease and injury including but not limited to acute respiratory distress syndrome (ARDS), CO VID infection, cytokine storms, sepsis and related conditions. These compositions include, but are not limited to, peptide variants and compositions that inhibit activity of a receptor complex formed by triggering receptors expressed on myeloid cells (TREM; i.e., TREM-1, TREM-2, TREM-3 or TREM-4) and DNAX activation protein of 12kDa (DAP 12).
-
公开(公告)号:WO2022239764A1
公开(公告)日:2022-11-17
申请号:PCT/JP2022/019785
申请日:2022-05-10
Applicant: O-Force合同会社
IPC: A61K38/08 , A61K38/10 , A61K38/16 , A61P25/16 , C07K7/04 , C07K7/06 , C07K7/08 , C07K14/00 , G01N21/64
Abstract: パーキンソン病等の原因となるα-シヌクレインの凝集を抑制する新たな薬剤を提供する。 本発明のα-シヌクレインの凝集抑制剤は、下記(A1)、(A2)、(B1)または(B2)のペプチドを含むことを特徴とする。 (A1)配列番号1のアミノ酸配列において、連続する6残基以上のアミノ酸配列からなるペプチド RETLVYLTHLDYDDTE (配列番号1) (A2)前記(A1)のアミノ酸配列において1~2個のアミノ酸が欠失、置換または付加されたアミノ酸配列からなるペプチド (B1)配列番号4のアミノ酸配列からなるペプチド YSNFNTDY (配列番号4) (B2)前記(B1)のアミノ酸配列において1~2個のアミノ酸が欠失、置換または付加されたアミノ酸配列からなるペプチド
-
公开(公告)号:WO2022205822A1
公开(公告)日:2022-10-06
申请号:PCT/CN2021/122042
申请日:2021-09-30
Applicant: 杭州先端生物科技有限公司 , 江苏吉锐生物技术有限公司
Abstract: 本发明属于生物医药技术领域,提供了一种抑制新型冠状病毒感染的抗菌肽、其组合物及相关用途。所述组合物以抗菌肽为主要活性成分,添加药学上可接受的其他辅料、载体或辅助性成分。所述抗菌肽及其组合物具有抑制新型冠状病毒的作用,可用于预防和抑制由新型冠状病毒感染引起的疾病,安全性好、无激素、无抗生素。
-
-
-
-
-
-
-
-
-